(NASDAQ: MCRB) Seres Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Seres Therapeutics's earnings in 2025 is $72,951,000.On average, 3 Wall Street analysts forecast MCRB's earnings for 2025 to be -$14,611,962, with the lowest MCRB earnings forecast at -$20,870,489, and the highest MCRB earnings forecast at -$7,247,910. On average, 2 Wall Street analysts forecast MCRB's earnings for 2026 to be -$96,667,912, with the lowest MCRB earnings forecast at -$108,194,709, and the highest MCRB earnings forecast at -$85,141,115.
In 2027, MCRB is forecast to generate -$15,369,063 in earnings, with the lowest earnings forecast at -$15,369,063 and the highest earnings forecast at -$15,369,063.